HAO1 and primary hyperoxaluria type 1: In November of 2020, Lumasiram (OxlumoTM), a small interfering RNA (siRNA) against the mRNA for the hydroxyacid oxidase 1 (HAO1) gene that encodes glycolate oxidase was approved for the treatment of all patients with PH1, including children [80].